Top ▲
Gene and Protein Information  |
|||||||
| Species | TM | P Loops | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 24 | 4 | 2016 | 3p22.2 | SCN5A | sodium voltage-gated channel alpha subunit 5 | |
| Mouse | 24 | 4 | 2019 | 9 71.33 cM | Scn5a | sodium channel, voltage-gated, type V, alpha | |
| Rat | 24 | 4 | 2019 | 8q32 | Scn5a | sodium voltage-gated channel alpha subunit 5 | 16,39 |
| Previous and Unofficial Names |
| cardiac sodium channel | Skm2 | SkMII | sodium channel protein type 5 | sodium channel, voltage-gated, type V, alpha subunit | sodium channel, voltage gated, type V alpha subunit | sodium channel |
| Database Links |
|
| Alphafold | Q14524 (Hs), Q9JJV9 (Mm), P15389 (Rn) |
| ChEMBL Target | CHEMBL1980 (Hs), CHEMBL4630764 (Mm), CHEMBL3866 (Rn) |
| DrugBank Target | Q14524 (Hs) |
| Ensembl Gene | ENSG00000183873 (Hs), ENSMUSG00000032511 (Mm), ENSRNOG00000015049 (Rn) |
| Entrez Gene | 6331 (Hs), 20271 (Mm), 25665 (Rn) |
| Human Protein Atlas | ENSG00000183873 (Hs) |
| KEGG Gene | hsa:6331 (Hs), mmu:20271 (Mm), rno:25665 (Rn) |
| OMIM | 600163 (Hs) |
| Orphanet | ORPHA118513 (Hs) |
| Pharos | Q14524 (Hs) |
| RefSeq Nucleotide | NM_001099405 (Hs), NM_198056 (Hs), NM_000335 (Hs), NM_001160160 (Hs), NM_001099404 (Hs), NM_001160161 (Hs), NM_021544 (Mm), NM_013125 (Rn) |
| RefSeq Protein | NP_001092875 (Hs), NP_000326 (Hs), NP_001153632 (Hs), NP_001153633 (Hs), NP_932173 (Hs), NP_001092874 (Hs), NP_067519 (Mm), NP_037257 (Rn) |
| UniProtKB | Q14524 (Hs), Q9JJV9 (Mm), P15389 (Rn) |
| Wikipedia | SCN5A (Hs) |
| Selected 3D Structures |
|||||||||||||
|
|
||||||||||||
| Associated Proteins |
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Associated Protein Comments | ||||||||||||||||||||||||||
| Subunit associations are based on co-localization, co-expression in heterologous cells, and co-immunoprecipitation. No biochemical data on Nav1.5 purified from cardiac tissue are available. | ||||||||||||||||||||||||||
| Functional Characteristics |
|
| Activation V0.5 = -26 mV. Fast inactivation (τ = 1 ms for peak sodium current). | |
| Ion Selectivity and Conductance Comments |
| Single channel conductance for Nav1.5 is ~20 pS and is not reported to be depended on species [1956,2884,2885] |
| Voltage Dependence |
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
Download all structure-activity data for this target as a CSV file 
| Activators | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| View species-specific activator tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gating inhibitors
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| View species-specific gating inhibitor tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gating Inhibitor Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| μ-conotoxin SmIIIA toxin has much higher affinity for tetrodotoxin-sensitive Nav channels, including Nav1.1, Nav1.2, Nav1.3, and Nav1.4. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Channel Blockers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| View species-specific channel blocker tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| Nav1.5 is involved in the positive selection of CD4+ T cells [19]. |
| Cell Type Associations | ||||
|
| Tissue Distribution
|
||||||||
|
||||||||
|
||||||||
|
| Physiological Functions
|
||||||||
|
||||||||
|
| Physiological Consequences of Altering Gene Expression
|
||||||||||
|
| Phenotypes, Alleles and Disease Models
|
Mouse data from MGI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Biologically Significant Variants
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
1. Ackerman MJ, Siu BL, Sturner WQ, Tester DJ, Valdivia CR, Makielski JC, Towbin JA. (2001) Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA, 286 (18): 2264-9. [PMID:11710892]
2. Belardinelli L, Rajamani S, Zeng D. (2015) Compound and methods for treating long qt syndrome. Patent number: US20150038489 A1. Assignee: Gilead Sciences, Inc.. Priority date: 01/08/2013. Publication date: 05/02/2015.
3. Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, George Jr AL. (2003) Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest, 112 (7): 1019-28. [PMID:14523039]
4. Biskup C, Zimmer T, Benndorf K. (2004) FRET between cardiac Na+ channel subunits measured with a confocal microscope and a streak camera. Nat Biotechnol, 22 (2): 220-4. [PMID:14730318]
5. Bossu A, Houtman MJC, Meijborg VMF, Varkevisser R, Beekman HDM, Dunnink A, de Bakker JMT, Mollova N, Rajamani S, Belardinelli L et al.. (2018) Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia. Br J Pharmacol, 175 (12): 2470-2482. [PMID:29582428]
6. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G et al.. (1998) Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature, 392 (6673): 293-6. [PMID:9521325]
7. Cohen SA. (1996) Immunocytochemical localization of rH1 sodium channel in adult rat heart atria and ventricle. Presence in terminal intercalated disks. Circulation, 94 (12): 3083-6. [PMID:8989112]
8. Cribbs LL, Satin J, Fozzard HA, Rogart RB. (1990) Functional expression of the rat heart I Na+ channel isoform. Demonstration of properties characteristic of native cardiac Na+ channels. FEBS Lett, 275 (1-2): 195-200. [PMID:2175715]
9. Dhar Malhotra J, Chen C, Rivolta I, Abriel H, Malhotra R, Mattei LN, Brosius FC, Kass RS, Isom LL. (2001) Characterization of sodium channel alpha- and beta-subunits in rat and mouse cardiac myocytes. Circulation, 103 (9): 1303-10. [PMID:11238277]
10. Fahmi AI, Patel M, Stevens EB, Fowden AL, John JE, Lee K, Pinnock R, Morgan K, Jackson AP, Vandenberg JI. (2001) The sodium channel beta-subunit SCN3b modulates the kinetics of SCN5a and is expressed heterogeneously in sheep heart. J Physiol (Lond.), 537 (Pt 3): 693-700. [PMID:11744748]
11. Focken T, Chowdhury S, Zenova A, Grimwood ME, Chabot C, Sheng T, Hemeon I, Decker SM, Wilson M, Bichler P et al.. (2018) Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain. J Med Chem, 61 (11): 4810-4831. [PMID:29737846]
12. Hedley PL, Jørgensen P, Schlamowitz S, Moolman-Smook J, Kanters JK, Corfield VA, Christiansen M. (2009) The genetic basis of Brugada syndrome: a mutation update. Hum Mutat, 30 (9): 1256-66. [PMID:19606473]
13. Hill RJ, Duff HJ, Sheldon RS. (1989) Class I antiarrhythmic drug receptor: biochemical evidence for state-dependent interaction with quinidine and lidocaine. Mol Pharmacol, 36 (1): 150-9. [PMID:2546048]
14. Jiang D, Shi H, Tonggu L, Gamal El-Din TM, Lenaeus MJ, Zhao Y, Yoshioka C, Zheng N, Catterall WA. (2020) Structure of the Cardiac Sodium Channel. Cell, 180 (1): 122-134.e10. [PMID:31866066]
15. Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, Wittmann M. (2022) The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia, 63 (3): 697-708. [PMID:35037706]
16. Kallen RG, Sheng ZH, Yang J, Chen LQ, Rogart RB, Barchi RL. (1990) Primary structure and expression of a sodium channel characteristic of denervated and immature rat skeletal muscle. Neuron, 4 (2): 233-42. [PMID:2155010]
17. Ko SH, Lenkowski PW, Lee HC, Mounsey JP, Patel MK. (2005) Modulation of Na(v)1.5 by beta1-- and beta3-subunit co-expression in mammalian cells. Pflugers Arch, 449 (4): 403-12. [PMID:15455233]
18. Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Notte GT, Kalla R, Jiang RH, Li X, Perry TD, Avila B et al.. (2016) Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine. Bioorg Med Chem Lett, 26 (13): 3202-3206. [PMID:27080178]
19. Lo WL, Donermeyer DL, Allen PM. (2012) A voltage-gated sodium channel is essential for the positive selection of CD4(+) T cells. Nat Immunol, 13 (9): 880-7. [PMID:22842345]
20. Maier SK, Westenbroek RE, McCormick KA, Curtis R, Scheuer T, Catterall WA. (2004) Distinct subcellular localization of different sodium channel alpha and beta subunits in single ventricular myocytes from mouse heart. Circulation, 109 (11): 1421-7. [PMID:15007009]
21. Maier SK, Westenbroek RE, Schenkman KA, Feigl EO, Scheuer T, Catterall WA. (2002) An unexpected role for brain-type sodium channels in coupling of cell surface depolarization to contraction in the heart. Proc Natl Acad Sci USA, 99 (6): 4073-8. [PMID:11891345]
22. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara S, Mochizuki N, Makiyama T, Itoh H, Christiansen M, McKeown P, Miyamoto K, Kamakura S, Tsutsui H, Schwartz PJ, George AL, Roden DM. (2008) The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest, 118 (6): 2219-29. [PMID:18451998]
23. Makita N, Sasaki K, Groenewegen WA, Yokota T, Yokoshiki H, Murakami T, Tsutsui H. (2005) Congenital atrial standstill associated with coinheritance of a novel SCN5A mutation and connexin 40 polymorphisms. Heart Rhythm, 2 (10): 1128-34. [PMID:16188595]
24. Makita N, Shirai N, Nagashima M, Matsuoka R, Yamada Y, Tohse N, Kitabatake A. (1998) A de novo missense mutation of human cardiac Na+ channel exhibiting novel molecular mechanisms of long QT syndrome. FEBS Lett, 423 (1): 5-9. [PMID:9506831]
25. Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K, Kobori A, Ninomiya T, Yoshida H, Takano M et al.. (2005) High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol, 46 (11): 2100-6. [PMID:16325048]
26. Malhotra JD, Thyagarajan V, Chen C, Isom LL. (2004) Tyrosine-phosphorylated and nonphosphorylated sodium channel beta1 subunits are differentially localized in cardiac myocytes. J Biol Chem, 279 (39): 40748-54. [PMID:15272007]
27. Mantegazza M, Yu FH, Catterall WA, Scheuer T. (2001) Role of the C-terminal domain in inactivation of brain and cardiac sodium channels. Proc Natl Acad Sci USA, 98 (26): 15348-53. [PMID:11742069]
28. McKerrall SJ, Nguyen T, Lai KW, Bergeron P, Deng L, DiPasquale A, Chang JH, Chen J, Chernov-Rogan T, Hackos DH et al.. (2019) Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain. J Med Chem, 62 (8): 4091-4109. [PMID:30943032]
29. Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros S, Tusié-Luna MT, Makielski JC, Ackerman MJ. (2007) SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation, 116 (2): 134-42. [PMID:17592081]
30. Middleton RE, Warren VA, Kraus RL, Hwang JC, Liu CJ, Dai G, Brochu RM, Kohler MG, Gao YD, Garsky VM et al.. (2002) Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry, 41 (50): 14734-47. [PMID:12475222]
31. Mohler PJ, Rivolta I, Napolitano C, LeMaillet G, Lambert S, Priori SG, Bennett V. (2004) Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci USA, 101 (50): 17533-8. [PMID:15579534]
32. Mulcahy JV, Pajouhesh H, Beckley JT, Delwig A, Du Bois J, Hunter JC. (2019) Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform NaV1.7. J Med Chem, 62 (19): 8695-8710. [PMID:31012583]
33. Márquez MF, Bonny A, Hernández-Castillo E, De Sisti A, Gómez-Flores J, Nava S, Hidden-Lucet F, Iturralde P, Cárdenas M, Tonet J. (2012) Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm, 9 (12): 1995-2000. [PMID:23059185]
34. Nilius B, Boldt W, Benndorf K. (1986) Properties of aconitine-modified sodium channels in single cells of mouse ventricular myocardium. Gen Physiol Biophys, 5 (5): 473-84. [PMID:2433183]
35. Niu DM, Hwang B, Hwang HW, Wang NH, Wu JY, Lee PC, Chien JC, Shieh RC, Chen YT. (2006) A common SCN5A polymorphism attenuates a severe cardiac phenotype caused by a nonsense SCN5A mutation in a Chinese family with an inherited cardiac conduction defect. J Med Genet, 43 (10): 817-21. [PMID:16707561]
36. Nuss HB, Tomaselli GF, Marbán E. (1995) Cardiac sodium channels (hH1) are intrinsically more sensitive to block by lidocaine than are skeletal muscle (mu 1) channels. J Gen Physiol, 106 (6): 1193-209. [PMID:8786356]
37. Oliveira JS, Redaelli E, Zaharenko AJ, Cassulini RR, Konno K, Pimenta DC, Freitas JC, Clare JJ, Wanke E. (2004) Binding specificity of sea anemone toxins to Nav 1.1-1.6 sodium channels: unexpected contributions from differences in the IV/S3-S4 outer loop. J Biol Chem, 279 (32): 33323-35. [PMID:15169781]
38. Rivolta I, Abriel H, Tateyama M, Liu H, Memmi M, Vardas P, Napolitano C, Priori SG, Kass RS. (2001) Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem, 276 (33): 30623-30. [PMID:11410597]
39. Rogart RB, Cribbs LL, Muglia LK, Kephart DD, Kaiser MW. (1989) Molecular cloning of a putative tetrodotoxin-resistant rat heart Na+ channel isoform. Proc Natl Acad Sci USA, 86 (20): 8170-4. [PMID:2554302]
40. Rogers JC, Qu Y, Tanada TN, Scheuer T, Catterall WA. (1996) Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit. J Biol Chem, 271 (27): 15950-62. [PMID:8663157]
41. Rong M, Chen J, Tao H, Wu Y, Jiang P, Lu M, Su H, Chi Y, Cai T, Zhao L et al.. (2011) Molecular basis of the tarantula toxin jingzhaotoxin-III (β-TRTX-Cj1α) interacting with voltage sensors in sodium channel subtype Nav1.5. FASEB J, 25 (9): 3177-85. [PMID:21665957]
42. Rook MB, Bezzina Alshinawi C, Groenewegen WA, van Gelder IC, van Ginneken AC, Jongsma HJ, Mannens MM, Wilde AA. (1999) Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res, 44 (3): 507-17. [PMID:10690282]
43. Royer A, van Veen TA, Le Bouter S, Marionneau C, Griol-Charhbili V, Léoni AL, Steenman M, van Rijen HV, Demolombe S, Goddard CA, Richer C, Escoubet B, Jarry-Guichard T, Colledge WH, Gros D, de Bakker JM, Grace AA, Escande D, Charpentier F. (2005) Mouse model of SCN5A-linked hereditary Lenègre's disease: age-related conduction slowing and myocardial fibrosis. Circulation, 111 (14): 1738-46. [PMID:15809371]
44. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. (2007) Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation, 116 (10): 1137-44. [PMID:17698727]
45. Ruan Y, Liu N, Priori SG. (2009) Sodium channel mutations and arrhythmias. Nat Rev Cardiol, 6 (5): 337-48. [PMID:19377496]
46. Schott JJ, Alshinawi C, Kyndt F, Probst V, Hoorntje TM, Hulsbeek M, Wilde AA, Escande D, Mannens MM, Le Marec H. (1999) Cardiac conduction defects associate with mutations in SCN5A. Nat Genet, 23 (1): 20-1. [PMID:10471492]
47. Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, Stramba-Badiale M, Richard TA, Berti MR, Bloise R. (2000) A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med, 343 (4): 262-7. [PMID:10911008]
48. Schwoerer AP, Scheel H, Friederich P. (2015) A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels. Anesth Analg, 120 (6): 1226-34. [PMID:25692452]
49. Sheets MF, Hanck DA. (1999) Gating of skeletal and cardiac muscle sodium channels in mammalian cells. J Physiol (Lond.), 514 ( Pt 2): 425-36. [PMID:9852324]
50. Sheldon RS, Cannon NJ, Duff HJ. (1986) Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels. Mol Pharmacol, 30 (6): 617-23. [PMID:2431264]
51. Sheldon RS, Duff HJ, Thakore E, Hill RJ. (1994) Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels. J Pharmacol Exp Ther, 268 (1): 187-94. [PMID:8301556]
52. Sheldon RS, Hill RJ, Cannon NJ, Duff HJ. (1989) Amiodarone: biochemical evidence for binding to a receptor for class I drugs associated with the rat cardiac sodium channel. Circ Res, 65 (2): 477-82. [PMID:2546697]
53. Shin DJ, Jang Y, Park HY, Lee JE, Yang K, Kim E, Bae Y, Kim J, Kim J, Kim SS, Lee MH, Chahine M, Yoon SK. (2004) Genetic analysis of the cardiac sodium channel gene SCN5A in Koreans with Brugada syndrome. J Hum Genet, 49 (10): 573-8. [PMID:15338453]
54. Smits JP, Koopmann TT, Wilders R, Veldkamp MW, Opthof T, Bhuiyan ZA, Mannens MM, Balser JR, Tan HL, Bezzina CR et al.. (2005) A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. J Mol Cell Cardiol, 38 (6): 969-81. [PMID:15910881]
55. Vaeth M, Feske S. (2018) Ion channelopathies of the immune system. Curr Opin Immunol, 52: 39-50. [PMID:29635109]
56. Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, Nademanee K, Brugada R, Brugada J, Veerakul G, Li H, Bowles NE, Brugada P, Antzelevitch C, Towbin JA. (2002) Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet, 11 (3): 337-45. [PMID:11823453]
57. Wang DW, Viswanathan PC, Balser JR, George Jr AL, Benson DW. (2002) Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation, 105 (3): 341-6. [PMID:11804990]
58. Wang G, Dugas M, Armah BI, Honerjäger P. (1990) Sodium channel comodification with full activator reveals veratridine reaction dynamics. Mol Pharmacol, 37 (2): 144-8. [PMID:2154667]
59. Wang Q, Chen S, Chen Q, Wan X, Shen J, Hoeltge GA, Timur AA, Keating MT, Kirsch GE. (2004) The common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel. J Med Genet, 41 (5): e66. [PMID:15121794]
60. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT. (1995) Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet, 4 (9): 1603-7. [PMID:8541846]
61. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. (1995) SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell, 80 (5): 805-11. [PMID:7889574]
62. Wei J, Wang DW, Alings M, Fish F, Wathen M, Roden DM, George AL. (1999) Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation, 99 (24): 3165-71. [PMID:10377081]
63. Wilson MJ, Yoshikami D, Azam L, Gajewiak J, Olivera BM, Bulaj G, Zhang MM. (2011) μ-Conotoxins that differentially block sodium channels NaV1.1 through 1.8 identify those responsible for action potentials in sciatic nerve. Proc Natl Acad Sci USA, 108 (25): 10302-7. [PMID:21652775]
64. Wright SN. (2002) Comparison of aconitine-modified human heart (hH1) and rat skeletal (mu1) muscle Na+ channels: an important role for external Na+ ions. J Physiol (Lond.), 538 (Pt 3): 759-71. [PMID:11826163]
65. Wu B, Murray JK, Andrews KL, Sham K, Long J, Aral J, Ligutti J, Amagasu S, Liu D, Zou A et al.. (2018) Discovery of Tarantula Venom-Derived NaV1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis. J Med Chem, 61 (21): 9500-9512. [PMID:30346167]
66. Zeng D, Kyle JW, Martin RL, Ambler KS, Hanck DA. (1996) Cardiac sodium channels expressed in a peripheral neurotumor-derived cell line, RT4-B8. Am J Physiol, 270 (5 Pt 1): C1522-31. [PMID:8967455]
67. Zimmer T, Benndorf K. (2007) The intracellular domain of the beta 2 subunit modulates the gating of cardiac Na v 1.5 channels. Biophys J, 92 (11): 3885-92. [PMID:17369409]
68. Zimmer T, Biskup C, Bollensdorff C, Benndorf K. (2002) The beta1 subunit but not the beta2 subunit colocalizes with the human heart Na+ channel (hH1) already within the endoplasmic reticulum. J Membr Biol, 186 (1): 13-21. [PMID:11891585]
target has curated data in GtoImmuPdb
